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Open access under the ElPlasmepsin IV (PM IV) is a potential target for developing drugs against malaria. This Letter presents
results of QM/MM dynamic simulations applied to the study of the protonation state of two aspartates
(Asp34 and Asp214) catalytic residues of PM IV in complex with KNI-764 inhibitor. The potential of mean
force proﬁle was used to assign the protonation state of the two catalytic aspartates in PM IV–KNI-764
complex. The results indicate that protonation of the 214 residue is more favorable. In addition, energy
terms decomposition was used to explore key interactions between the main residues and KNI-764
inhibitor.
 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Malaria is the largest tropical parasitic disease in the world,
with the continents most affected being Africa, some regions of
Asia, Central and South America and some Caribbean Islands. Data
from the World Health Organization (WHO) suggest an estimated
300–660 million cases recorded yearly around the world, with an
annual occurrence of mortality in excess of 2.5 million [1,2]. The
agent that causes malaria in humans belongs to the genus of pro-
tozoa known as Plasmodium, four types of which infect humans:
P. falciparum, P. vivax, P. malariae and P. ovale, with the ﬁrst being
the greatest cause of deaths in humans [3]. The parasite causes
the disease during its intra-erythrocytic cycle, by consuming hu-
man hemoglobin for its growth and maturation. The degradation
of hemoglobin is performed by a number of proteases called
plasmepsins in acid food vacuoles [4].
Different plasmepsin molecules have been identiﬁed in the
P. falciparum genome and four of them are active in the food vacu-
ole during the intra-erythrocytic stage. The Plasmepsin molecules
are also capable of several other cleavages after the initial event
[5,6]. These enzymes have similarities, which can demonstrate bio-
logical activities that are of interest for research [7,8].
Recently, the ﬁrst PM IV crystallography of the enzyme com-
plexed with an allophenylnorstatine inhibitor was reported by
Clement and co-workers [9]. The great interest in this class of
inhibitors is due to their efﬁciency in front of the enzymes in the
P. falciparum [10] food vacuole, and the original purpose for this
inhibitor is considered to be the inhibition of HIV-1 protease en-sevier OA license.zymes [11,12]. Crystallographic results were observed in the com-
plex formed by the PM IV enzyme inhibitor KNI-764, which was in
a different position from what is expected when compared to a
previous model of this analysis. This new fact demonstrates the
importance of further study in order to obtain a more accurate
understanding of the interaction occurring in the formation of this
complex [13].
Several computational methods, including molecular docking
and classical molecular dynamics [4,10,14–16] simulations have
been employed to elucidate the binding mode of PM inhibitors,
and to calculate the free energy proﬁle for the catalytic mechanism
[17]. One option that has been utilized to accurately describe the
enzyme–inhibitor complex, consists of using the protonation state
from aspartates 34 and 214. Friedman and Caﬂisch [18] conducted
studies of the PM II protonation state with classical MD simula-
tions and obtained results in a favorable protonation to Asp214
when activating the enzyme. In a recent study, Gutiérrez-de-Terán
and co-workers [14] performed a computational analysis for the
PM IV–KNI-764 complex and a study was also conducted with clas-
sical MD aiming to bind afﬁnities using linear interaction energy
(LIE). The authors showed that the protonation of Asp214 favors
a stable active site structure.
Recent studies have applied hybrid QuantumMechanics/Molec-
ular Mechanics (QM/MM) methodology with great success in the
study of protein–ligand interactions in the HIV-1 protease system
[19], OH transfer in Flavin-dependent oxidoreductases p-Hydroxy-
benzoate hydroxylase and others [20]. When procedures using this
methodology are performed, hybrid QM/MM species or substrates
are described by QM. This description includes quantum effects
such as ligand polarization upon binding [21], with the protein
and solvent environment being represented by means of the MM
force ﬁeld.
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molecular dynamics (MD) simulations to study the details of
the PM IV–KNI-764 interactions and investigate the protonation
state of the two catalytic aspartates, Asp34 and Asp214, in PM
IV–KNI-764 complex. Moreover, contribution of individual resi-
dues to the total inhibitor–protein interaction energy have been
computed between KNI-764 and some key residues inside the
binding pocket, as well as an estimation of the inhibitor–protein
electrostatic binding free energy that was used to explain the
difference in the protonation state of the Asp34 and Asp214. In
addition, we have computed the potential of mean force (PMF)
proﬁle to assign the main protonation state of these aspartates
in PM IV–KNI-764 complex.2. Methodology
2.1. Model
The initial structure was constructed from the A-chain of the
X-ray crystal structure complexed with the allophenylnorstatine
inhibitor (KNI-764), code PBD 2ANL [9]. Once it became possible
to exchange standard pKa values of the ionisable group with local
protein environments [22], an accurate assignment of the proton-
ation states of the amino acids at pH 7 was carried out by recal-
culating the standard pKa values of the titratable amino acids
using the ‘cluster method’ [22], as implemented by Field and
co-workers [23]. In this methodology, each titratable residue in
the protein is perturbed by the electrostatic effects of the protein
environment. We have also performed calculation of pKa values of
amino acids within the empirical propKa program of Li and co-
workers [24].
To perform a theoretical study of an enzymatic environment
QM/MM was employed using the fDynamo library [29]. The PM
IV enzyme consists of 327 amino acid residues, whose catalytic
residues are Asp34 and Asp214, and 7 molecules of water, called
water of crystallization. Its active site is composed of an inhibitor
called KNI-764, which was crystallized with the enzyme, forming
the enzyme–inhibitor complex. During preparation of the enzyme
for the MD simulation, hydrogen atoms were added to the system,
so that the pH was neutral. The system was embedded in a cubic
box (80 Å side) containing 19,418 atoms in order to simulate the
reaction medium. The ﬁnal system contains a total of 63,515Scheme 1. Structures of the A and B models, where HE1-OD1 of Asp214 (R1) and HE2-O
Asp34 in 2D.atoms, where 83 atoms are in QM region (KNI-764 inhibitor,
Asp34 and Asp214).2.2. QM/MM MD simulations
For the hybrid QM/MM MD calculations, we have two simula-
tion models, A (protonating Asp214) and B (protonating Asp34)
(Scheme 1), where the atoms of the inhibitor and Asp214 and
Asp34 were selected for treatment by QM. To saturate the valence
of the QM/MM frontier in the ﬁrst model, we used a link atom [25],
placed between the Ca and Cb atoms of Asp214 and Asp34 residues.
The semiempirical AM1 Hamiltonian was employed to describe the
QM part [26], while the rest of the system (protein plus water mol-
ecules) was described using the OPLS-AA [27] and TIP3P [28] force
ﬁelds, respectively, as implemented in the fDynamo library [29].
Due to the amount of degrees of freedom, any residue 25 Å
apart from any of the atoms of the initial inhibitor was selected
to be kept frozen (which represents a total of 50,865 atoms) in
the remaining calculations in order to make the model computa-
tionally feasible. Cutoffs for the non-bonding interactions were ap-
plied using a switching scheme, within a range radius from 18.0 to
14.5 Å.
Once the systems were pre-equilibrated, 1.6 ns of QM/MM
MD were run at a temperature of 300 K. The computed RMSD
for the protein during the last 100 ps rendered a value that
was always below 0.8 Å, while the RMS of the temperature along
the different equilibration steps was always lower than 2.5 K and
the variation coefﬁcient of the potential energy during the
dynamics simulations was never greater higher than 0.3%. The
potential energy of our scheme [30] is derived from the standard
QM/MM formulation (for more details see Ref. [30]). In addition,
it must be pointed out that, because the use of high level Ham-
iltonians for performing hybrid MD is currently prohibitive, the
electrostatic free energy has been evaluated using the semiem-
pirical AM1 Hamiltonian. In addition, the interaction energy be-
tween the inhibitor and the environment was computed by
residue, where the atoms of the inhibitor and Asp214 and
Asp34 were selected for treatment using QM. Finally, the inter-
nal energy and the contribution of individual amino acid resi-
dues were calculated using the hybrid density functional
theory (DFT) [31], where the B3LYP functional within the
6-31G(d,p) basis set has been employed to perform QM/MMD2 of Asp34 (R2) coordinates corresponding to the proton transfer from Asp214 to
Figure 1. Potential of mean force proﬁle for proton transference from Asp214 to
Asp34 (transformation between A and B forms). Relative energies in kJ mol1 and
reaction coordinate (R1–R2) in Å.
Natália de Farias Silva et al. / Chemical Physics Letters 509 (2011) 169–174 171internal energy calculations in order to evaluate the appropriate-
ness of the AM1/MM potentials for describing the non-bonded
interactions between the inhibitor and the protein.
2.3. Potential of Mean Force
In order to obtain the free energy change associated to the pro-
ton transfer from Asp214 to Asp34 (transformation between A and
B forms), we have computed the corresponding potential of mean
force (PMF) [32] using the weighted histogram analysis method
(WHAM) combined with the umbrella sampling approach [33] as
implemented in fDynamo [29]. In this PMF, the distinguishing
reaction coordinates was the antisymmetric combination of the
distances HE1-OD1 of Asp214 (R1) and HE2-OD2 of Asp34 (R2)
coordinates (see Scheme 1) corresponding to the proton transfer
from Asp214 to Asp34. A total of 40 simulations were performed
at different values of R1 and R2 (in a range from 1.5 to +1.5 Å),
with an umbrella force constant of 2800 kJ mol1 A2. In each win-
dow, 5 ps of relaxation were followed by 10 ps of production QM/
MMMDwith a time step of 0.5 ps due to the nature of the chemical
step involving a hydrogen transfer.Table 1
Binding free energies (DGElect  AM1/MM) obtained from electrostatic FEP calculations at
the AM1/MM level and averaged interaction energies computed during the last 100 ps
of AM1/MM MD simulations (EElect  AM1/MM).
Energies (in kJ mol1) Model
A B
DGElect  AM1/MM 136.42 125.30
EElect  AM1/MM 581.21 530.80
Figure 2. Details of interaction between KNI-764 and key residues obtained after 1.6 ns
(key interatomic distances, in Å) for A form: (a) KNI-764 and Asp34, Asp214 and Thr217
key residues; (d) KNI-764 and one water and (e) KNI-764 and Gly78 and Ser79.3. Results and discussion
3.1. pKa calculations
As mentioned in the previous section, we performed pKa calcu-
lations for PM IV complexed with the KNI-764 inhibitor using ‘clus-
ter methods’ and propKa, once standard pKa values of ionisable
groups can be shifted by the local protein environment. According
to these methods, the Asp214 residue was found to be protonated,
while Asp34 residue was found be deprotonated (Supporting infor-
mation). Interestingly, Asp214 and Asp34 have been proposed asof AM1/MM MD simulations and representation of the most important interactions
; (b) KNI-764 and two waters; (c) structure of PM IV–KNI-764 complex showing all
Figure 3. (a) Contributions of individual amino acid residues to inhibitor interac-
tion energy (in kJ mol1) computed during the last 100 ps of AM1/MM MD
simulations for A form (a) and (b) computed using DFT/MM from structures
optimized after 1.6 ns B3LYP/MM MD simulations for A form (in kJ mol1).
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negatively charged. Thus the correct protonation state for both of
these residues is essential for a realistic modeling of the binding
site [11]. Consequently, we have considered the PM IV–KNI-764
complex using two states of protonation, Asp214 (model A) and
Asp34 (model B) protonated (see Scheme 1). These results are
qualitatively in agreement, predicting the same protonation state
for a number of residues at the selected pH of the simulations.
Thus, according to these results, most residues were found in their
standard protonation state.
3.2. Protonation state of PM IV
Protonation of the catalytic residues in PMs enzymes is directly
associated with the presence and type of inhibitor bound; thus it
can be concluded that there is a unique model capable of satisfac-
torily describing the protonation state of key aspartates such as
Asp214 and Asp34 [14,18]. In the present study, electrostatic con-
tribution to the free energy in the protein–substrate interaction,
obtained from the free energy perturbation (FEP) calculations at
AM1/MM level for A and B models reveals that a more stable form
of PM IV–KNI-764 is obtained from protonation of Asp214 residue,
which is consistent with the literature [14,18]. The difference ob-
served between these models is 11.12 kJ mol1 (Table 1). Obvi-
ously, the FEP calculation is only one of the electrostatic
contributions to the total binding free energy. We also calculated
protein interaction energies Elect-AM1/MM computed during the
last 100 ps of AM1/MM MD simulations (Table 1). The result re-
veals that a more stable form of PM IV–KNI-764 was obtained
when Asp214 was considered protonated. Thus, we can conclude
that different methodologies presented the same tendencies, in
accordance with the literature [14].
Based on the results and observations described above, we
decided to trace the potential of mean force (PMF) corresponding
to the proton transfer from the carboxylate oxygen atom OD1 of
Asp214 to carboxylate oxygen atom OD2 of Asp34 (transforma-
tion from A to B form). As shown in the PMF proﬁle (Figure 1),
inhibitor–protein complex is more stable in the A form than in
the B form by about 55 kJ mol1, in accordance with the results
of binding free energies. The free energy barrier for the A to B
conversion is 80 kJ mol1. Thus, this result indicates that the
protonation of Asp214 favors a stable active site structure. This
result is in agreement with previous HB analysis, which showed
that the protonation of Asp214 is more consistent with the
crystallographic data, which report the catalytic mechanism
[14]. These ﬁndings are also in agreement with our previous
QM/MM MD studies of interactions of EH58 inhibitor with PM
II protein [34].
3.3. PM IV–KNI-764 complex
The contributions of individual results for more stable PM
IV–KNI-764 complex (A form, obtained from protonation of
Asp214 residue) are discussed below and the results for B form
are discussed in Supporting Information.
In accordance with the results of the MD simulations of
QM/MM, diverse interaction keys have been found between PM
IV and KNI-764 inhibitor. As can be seen from Amodel (Figure 2a),
the hydroxyl group interacts with the OD2 oxygen atom of Asp34
(1.74 Å) through a hydrogen bond. Moreover, the hydroxyl group
also presents a hydrogen bond interaction with acid aspartic
protonated Asp214 (1.88 Å).
As observed in Figure 2c, other important residues present a
favorable interaction with the ligand, such as Gly78, Ser79 and
Thr217. The amino group of Gly78 and Ser79 residues interacts
with KNI-764 forming hydrogen bond at 2.02 and 2.20 Å in Amodel (Figure 2e). The hydroxyl group of Thr217 form hydrogen
bonds with inhibitor at 2.06 Å in A model (Figure 2a).
Contributions of individual amino acid residues to inhibitor
interaction energy obtained with AM1/MM for model A are shown
in Figure 3a, where negative values correspond to stabilization and
positive values correspond to destabilization of the protein–inhib-
itor complex. In this study, we also performed calculations with
B3LYP/MM in order to evaluate the appropriateness of the AM1/
MM potentials for describing the contributions of individual resi-
dues between the inhibitor and the protein (Figure 3b). The results
show that both AM1/MM and B3LYP/MM calculations produce
similar results. Analyzing the Figure 3, one may again clearly ob-
serve the presence of all amino acids cited above, showing how
the interactions between the residues are consistent with those
found in the literature [14].
In addition, we observe in Figure 2 that there are additional
water molecules that interact with the inhibitor stabilizing the
complex enzyme–inhibitor for A model (Figure 3). Three water
molecules are involved in hydrogen bonds with KNI-764 in the A
model (Figure 2b and d). Recent reports have proposed that water
molecules are important for stabilizing the interaction between the
ligand and the PMs enzymes class [18], in accordance with our the-
oretical simulations.
Finally, The catalytic aspartate protonation state has a strong
inﬂuence on the presence or absence of the hydrogen bonds be-
tween some residues [14,18]. As can be observed in Figures 2
and 3 and Supporting Information (Figures S3 and S4), the hydro-
gen bond in A and B models and inhibitors are practically equal.
Nevertheless, comparison between both models would require
simulation of the proton-transfer step from Asp214 to Asp34 or
vice versa, as discussed above.
Figure 4. MEP surfaces of (a) A form and (b) B form. The increase of negative charges goes from blue (positive) to red (negative). (For interpretation of references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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The Molecular Electrostatic Potential (MEP) is highly informa-
tive of the nuclear and electronic charge distribution of a given
molecule. MEP has been applied in studying biological interac-
tions and deﬁnition of molecular reactivity patterns [35,36]. In
this study, the MEP surfaces were computed under the effect
of the protein environment and were derived from B3LYP/
6-31G (d) calculations using Gaussian 03 [37] and visualized in
Gaussview 3.07 [38]. These surfaces correspond to an isodensity
value of 0.002 a.u. It is interesting to highlight the noncovalent
interactions occurring at the molecular surface. In Figure 4, the
most nucleophilic regions (negative electronic potential) are in
red, while the most electrophilic regions (positive electrostatic
potential) appear in blue. In the A model, the nucleophilic
region, can be found around the cetone group of the inhibitor
(Figure 4a). The electrophilic regions for the A model can be
found around the hydrogen atoms, mainly on atom H linked to
the oxygen atom (hydroxyl group) matching the positions of
Asp214 and Asp34, respectively. The positive region around the
H atom (hydroxyl group) is more positive in the A model,
because the hydroxyl group interacts with the OD2 oxygen atom
of Asp34 (1.74 Å) through a hydrogen bond. The nucleophilic
region can be found around the carbonyl groups of the inhibitor,
matching the positions of Gly78 and Ser79. These residues
interact with the inhibitor, forming a hydrogen bond as seen
in previous section. These MEPs are in accordance with our
results regarding contributions of individual amino acid residues
to inhibitor interaction and may be used as templates for design
of new inhibitors against malaria.4. Conclusions
In the research reported here, hybrid QM/MM MD simulations
have been carried out for PM IV complexed with KNI-764 using
two different forms for catalytic residues in the complex formed;
Asp214 protonated or Asp34 protonated (A and B models). The
analysis of individual interactions between the inhibitor and the
amino acids of the enzyme active site reveals how the inﬂuence
of Asp34, Gly78, Ser79, Asp214 and Thr217 appears to be crucial,
with the interactions established between the inhibitor and theses
residues being especially important. Moreover, the calculations
that determined the electrostatic contribution to the protein–li-
gand interaction free energies show that prevalence of the A form
is a better model for this inhibitor in the active site of PM IV. The
PMF proﬁle of the proton transfer between the carboxylate oxygen
atom of Asp214 to the carboxylate oxygen atom of Asp34 for inhib-
itor–protein complex shows that the A form is more stable than
the B form in accordance with the binding free energy results.
The results reported here are in agreement with the literature,
which demonstrates the efﬁciency of applying in this methodol-
ogy. Finally, the results are expected to provide useful information
for the rational design of new PM IV inhibitors.Acknowledgements
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